Introduction
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of resting monoclonal B cells and a very heterogeneous clinical outcome. This clinical heterogeneity can currently be predicted: the absence of hypersomatic mutation of the immunoglobulin heavy chain region 1 and zeta-associated protein 70 (ZAP70) expression in CLL B cells 2 are associated with poor outcomes. The initial cause of this disease remains an open question, but it is presently well accepted that accumulation of leukemic cells is partially explained by a defect in apoptosis. 3 A recent study suggested that CLL was not exclusively an accumulation disease but also a proliferative one. 4 Indeed, the bone marrow, lymph nodes and spleen are all sites of leukemic cell proliferation. 5 In the last few decades, many treatments have been proposed, such as alkylating agents, purine nucleoside analogues and monoclonal antibodies. 6 New agents such as bortezomib, flavopiridol, thalidomide and lenalidomide are also promising, but are still under investigation in clinical trials. [7] [8] [9] [10] Despite the introduction of these new treatments, CLL is still considered to be incurable. Furthermore, the continuous use of chemotherapeutic agents actually leads to development of resistance. 11 For these reasons, new therapeutic agents that restore apoptosis, inhibit proliferation and increase chemosensitivity with low toxicity must be analyzed for CLL management.
Valproic acid (VPA) is a short-chain fatty acid that has been used since decades as an anticonvulsant and was recently identified as a histone deacetylase inhibitor. By modifying the epigenetic code, this novel class of therapeutic agents could suppress aberrant gene expression or activate gene transcription inhibiting tumor growth. 12 The anti-tumor properties of VPA have been observed in many cancer types, such as prostate cancer, 13 breast cancer, 14 glioma, 15 neuroblastoma 16 and in hematological malignancies. [17] [18] [19] Recently, our group showed that VPA at low pharmacological concentration could induce apoptosis of CLL B cells in vitro. 20 Bokelmann and Mahlknecht 21 showed decrease in the BCL-2/Bax ratio in CLL B cells treated with VPA in vitro and Bouzar et al. 22 reported that valproate synergizes with purine nucleoside analogues to induce apoptosis of CLL B cells. Moreover, VPA has already been used in phase I/II clinical trials in combination with other classical chemotherapies such as purine analogues, 23, 24 anthracyclin 25 and chemoimmunotherapy. 26 VPA association with monoclonal antibodies is furthermore described in in vitro studies. 27, 28 Finally, VPA is well tolerated, and its effective concentration can be easily achieved in humans. All of these observations indicate that VPA could be a promising anticancer drug and strongly suggest the use of this epigenetic therapy in CLL treatment.
Materials and methods

Reagents
The sodium salt of VPA, flavopiridol (Sigma-Aldrich, Bornem, Belgium) and fludarabine (FLUDARA; Schering AG, Berlin, Germany) were dissolved in stock solution with water at 10 mM, 1mM and 100 mM, respectively. Thalidomide (THALOMID), lenalidomide (REVLIMID) (Celgene, Warren, NJ, USA) and bortezomib (VELCADE) (Millennium Pharmaceuticals, Cambridge, MA, USA) were dissolved in 10% dimethyl sulfoxide at a concentration of 1 mM. Stock solutions were stored at -20 1C.
Patients and sample collection
This study was approved by the Bordet Institute Ethics Committee and was based on peripheral blood samples obtained with informed consent from CLL patients who presented with a typical CD19 þ CD5 þ CD23 þ phenotype. All patients used in the study were untreated or had received no treatment for at least 6 months before the study. The characteristics of the patients included in the gene expression comparison are summarized in Table 1 . Peripheral blood mononuclear cells were isolated by density-gradient centrifugation over Linfosep (Biomedics, Madrid, Spain). B cells were purified by negative selection using the B Cell Isolation Kit II magnetic-bead system (MidiMACS, Miltenyi Biotec, Bergisch Gladbach, Germany), according to the manufacturer's instructions. Mean B-cell purity was 498% as measured by flow cytometry (FC). The expression of ZAP70 and CD38 protein using FC, ZAP70 and lipoprotein lipase (LPL) messenger RNA (mRNA) using real-time quantitative PCR (qPCR), classical cytogenetic by standard karyotype analysis, interphase fluorescence in situ hybridization (FISH) screening for most common aberrations, and immunoglobulin heavy chain region gene mutational analysis were performed as described earlier (Supplementary data 1).
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Apoptosis assessment and histone H4 acetylation by flow cytometry Apoptosis was quantified by measuring phosphatidylserine exposure using Annexin-V/propidium iodide (PI) double staining, according to standard procedures (Biosource International, Camarillo, CA, USA). It was also confirmed by evaluating the sub-G1 fraction after PI staining of permeabilized cells, corresponding to cells with fragmented DNA (Coulter, Hialeah, FL, USA). Cells were then analyzed by FC using a Coulter EPICS XL, and at least 20 000 cells from each sample were analyzed. Histone H4 acetylation was verified by FC as described by Ronzoni et al.
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Culture, RNA extraction and gene expression profile In all, 2 Â 10 6 per ml of purified CD19 þ cells were cultured in RPMI-1640 medium (Lonza, Verviers, Belgium) supplemented with 10% fetal bovine serum (Sigma-Aldrich) for 4 h with or without 1 mM of VPA. Total RNA was then extracted in a single step using TriPure Isolation Reagent (Roche Applied Science, Vilvoorde, Belgium). Microarray analysis was performed using 1.5 mg of RNA with an Affymetrix GeneChip Human Genome U133 Plus 2.0 Array, which contained more than 54 000 probe sets for analysis of about 47 000 transcripts (Affymetrix, High Wycombe, UK). Amplification, hybridization and scanning were all carried out according to standard Affymetrix protocols (www.affymetrix.com) (see also Supplementary data 2).
Bioinformatic analysis
Gene expression profiles were determined for 14 patients (seven ZAP70 þ and seven ZAP70 À patients), comparing cells treated with 1 mM VPA with untreated cells. We identified significant differences between sample groups using BRB array tools (Biometric Research Branch, National Cancer Institute). Only genes defined as 'present' by the Affymetrix algorithm in at least 25% of all experiments were considered for further analysis. We calculated paired two-sample t-tests (with a random variance model) of the two groups (treated and untreated with VPA) for each gene and addressed the multiple comparison problems by estimating the false discovery rate.
Validation by real-time PCR, western-blot analysis and caspase 8/9 activation assay We used 25 ng of complementary DNA (produced by standard reverse transcription) in a qPCR reaction with SYBR Green PCR Master Mix (Applied Biosystems, Rotterdam, The Netherlands) and 0.32 mM of gene-specific forward and reverse primers (Invitrogen Life technologies, Merelbeke, Belgium). Each reaction was run in duplicate with the 28 initial samples (14 patients, with and without VPA treatment). The primer sequences used are listed in Supplementary data 3. Standard qPCR was performed as described earlier. 29 However, it has been reported that housekeeping gene expression could be affected by histone deacetylase inhibitors. 33 Indeed, the expression of These values are expressed as fold of target gene expression in the calibrator cell line (Namalwa). c The optimal cutoff values for ZAP70 (qPCR), LPL (qPCR) and CD38 (FC), determined by ROC curve analysis, were 114, 6 and 7, respectively. d our endogenous control (cyclophilin A) was modulated by VPA treatment. Therefore, we compared gene expression using absolute quantification methods. For western-blot analysis, control or VPA-treated cultured CLL B cells were harvested after 72 h of treatment, lysed in RIPA buffer (150 mM NaCl, 1.0% NP-40, 0.5% deoxycholate, 0.1% SDS, 50 mM Tris [pH 8.0], 1 tablet of protease inhibitor for 10 mL of buffer), and the total protein in each sample was quantified using the Quick Start Bradford Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA, USA). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting were performed according to standard protocols. Anti-actin (C2Fsc-8432), anti-cyclin E (HE12Fsc-247), anti-cyclin D1 (72-13GFsc-450), anti-BCL2 (8C8Fsc-65392) and anti-Flip S/L (G-11Fsc-5276) were obtained from Santa Cruz (Heidelberg, Germany). These primary antibodies were probed with goat anti-mouse IgG horseradish peroxidase (Santa Cruz) secondary antibody and detected using the Supersignal West Pico chemiluminescence method (Pierce Chemicals Co, Rockford, IL, USA). Activated caspases 8 and 9 were detected using a colorimetric protease assay (ApoTarget, Invitrogen, Carlsbad, CA, USA). Caspase 8 and 9 proteolytic activity was evaluated after 4 and 24 h, respectively, of VPA treatment and compared with the levels of their untreated controls according to the manufacturer's procedures.
Stimulation and proliferation assay
Chronic lymphocytic leukemia B cells were stimulated as described earlier. 34 Briefly, 2 Â 10 6 per ml of CLL cells were stimulated using 100 U of IL2 (R&D Systems, Minneapolis, MN, USA) and 1 mM CpG oligonucleotides (ODN2006FInvivogen, San Diego, CA, USA). They were then incubated with or without 1 mM VPA for 48 h. Proliferation was measured using a WST1 (2-(4-lodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium) assay (Roche Diagnostics, Mannheim, Germany): 10 ml of WST1 reagent was directly added to the cultured cells, incubated for 4 h (at 37 1C, 5% CO 2 ) and quantified spectrophotometrically at 450 nm. The optical density results of WST1 were normalized to an unstimulated and untreated cell sample for each patient. Furthermore, these results were confirmed by cell cycle analysis using PI staining of permeabilized cells (Coulter) measured by FC.
Drug treatment and viability assay
In all, 2 Â 10 6 per ml of CLL B cells from 10 different patients (five ZAP70 þ and five ZAP70 À ) were incubated with eight increasing concentrations of fludarabine (from 0 to 20 mM), bortezomib (from 0 to 20 nM), flavopiridol (from 0 to 600 nM), thalidomide (from 0 to 100 nM) and lenalidomide (from 0 to 300 nM), with or without 1 mM VPA. After 24 h, viable cells were counted using a Trypan blue exclusion assay. The percentage of viable cells was normalized to untreated cells for each patient. The half maximal (50%) inhibitory concentration (IC50) was obtained by using the 'dose-response curvesFInhibition' function using the 'log(inhibitor) vs normalized response' equation
ðXÀlogIC50Þ Þ of GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA). Viability results were also confirmed using WST1 assay and 7AAD staining.
Statistical analysis
Significant differences were evaluated using the Student's paired t-test. All tests were two-sided. An effect was conside red to be statistically significant at Po0.05, and all analyses were performed with GraphPad Prism 5.0 software. -(a) and 12 ZAP70 þ (b) patients. The indicated apoptotic cell rate includes both PI þ (late apoptotis) and PI -(early apoptotis) cells. Statistical differences were assessed using the Student's paired t-test. A representative dot plot of annexin V/PI staining for samples untreated (c) and treated with 1 mM VPA (e) during 24 h is provided. These results were confirmed by a PI staining on permeabilized cells (d, f).
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Results
Valproic acid induces cytotoxicity, apoptosis and acetylation of histone H4
In our earlier work, we have shown that VPA had a cytotoxic effect by inducing apoptosis in CLL B cells independent of patient prognostic features. 20 We confirmed these results in this study by using a Trypan blue exclusion assay (data not shown), annexin V/PI staining and PI staining on permeabilized cells after 24 h of VPA treatment (Figure 1 ). After subtraction of spontaneous apoptosis, response to VPA evaluated in 24 CLL samples seems to be heterogeneous after 24 h (mean: 14.25%±1.95 of apoptotic cells, range 1-34%) but all patients finally responded after 48 h (mean: 24.50% ± 3.73 of apoptotic cells, range 8-59%), indicating that all patients were sensible to VPA, but with a different kinetic response. The increase of VPAinduced apoptosis between 24 and 48 h was also statistically significant (P ¼ 0.0109). Histone H4 acetylation was evaluated in B cells from eight CLL patient samples (CD19 þ 495%) cultured in vitro with or without 1 mM VPA for 4 h. VPA significantly enhanced histone H4 acetylation (P ¼ 0.0007) as shown by FC analysis (Supplementary data 4).
Comparison of gene set expression, real-time PCR and western-blot validation
In order to understand the early molecular mechanisms underlying the effects of VPA, we analyzed the gene expression profiles of 14 purified CD19 þ CLL samples (seven ZAP70 þ and seven ZAP70 À ) treated or untreated with 1 mM of VPA for 4 h. The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE14973 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc ¼ GSE14973). When we compared treated samples with their untreated counterparts, we found 16 531 differentially expressed probe sets (60%) with a false discovery rate o10%. A fold change cutoff of 1.5-fold (increase or decrease) allowed us to isolate 3830 probe sets (14%) differentially expressed with a false discovery rate o5% (see Supplementary data 5). Of these, 2194 (57%) were upregulated and 1636 (43%) were downregulated (Figure 2a ). When we compared gene modulation between cells from ZAP70 þ and ZAP70 À patients, we did not observe statistically significant differences, indicating that VPA had the same effect on patients with various prognoses and confirming our apoptosis data (Figure 2b) .
In order to validate this pattern, a panel of 24 genes (principally involved in apoptosis and proliferation pathways) was selected for qPCR validation from the 28 initial samples. All 24 genes were confirmed to be differentially expressed, indicating the robustness of our microarray data even for small fold changes lower than 1.5 ( Table 2) . We also confirmed protein expression modification after VPA treatment for key genes in apoptosis (decrease of BCL2, Flip L ) and in proliferation (increase of cyclin E and D1) pathways by western blot, indicating that VPA could also affect the protein level (Figure 3a) .
Valproic acid disturbs the balance between anti-and pro-apoptotic genes
The ratio of anti-and pro-apoptotic genes determines the tendency toward cell death or cell survival. In this study, we observed that VPA acted on an important number of genes involved in apoptosis: BCL2, XIAP, FLIP, BCL-xL, AVEN and cIAP mRNAs were all significantly downregulated, whereas CASP 2, 3, 8, 6, 9, and BAX, BAK, APAF1 and P53 were all significantly upregulated (Table 2 and Supplementary data 5).
Valproic acid activates the extrinsic apoptosis pathways
In total, 10 Â 10 6 cells were plated with (1 or 5 mM) or without VPA and the presence of activated caspases 8 and 9 was assessed after 4 and 24 h using a specific colorimetric assay. Optical density was normalized in each case with the untreated cell sample. As shown in Figures 3b and c, we observed an activation of caspase 8 but not caspase 9 after 24 h. After 4 h, activated caspase 8 was not yet detected, indicating that our gene expression profiles determined after 4 h were not an indication of apoptosis, but only of early VPA effect.
Valproic acid increases chemosensitivity
A concentration of 1 mM VPA was used with increasing concentrations of fludarabine, bortezomib, flavopiridol, thalidomide or lenalidomide on B cells from CLL patients (n ¼ 10; five ZAP70
þ and five ZAP70 -) to determine the IC50 of each drug with or without VPA. The addition of VPA significantly increased chemosensitivity to these five drugs (Figure 4 ). After normalization with the untreated controls, the percentages of viable cells determined by Trypan blue exclusion assay using Gene expression profile of VPA-treated CLL B cells B Stamatopoulos et al the IC50 obtained earlier (see Figure 4f ) were plotted (shown in Figure 4g ) to better appreciate the effect of VPA alone and in combination with other drugs. Viability results obtained with Trypan blue exclusion assay were also confirmed by WST1 assay and 7AAD staining (data not shown).
Valproic acid disturbs cell cycle gene expression
The cell cycle is very tightly regulated at various stages by cyclins, cyclin-dependent kinases (CDKs) and CDK inhibitors. Furthermore, each cycle stage involves the appearance of a specific cyclin, which is expressed and then subsequently degraded. With regard to our microarray data, we were able to show significant modulation of several mRNAs implicated in the cell cycle and proliferation. Moreover, these results were confirmed by qPCR ( Table 2) . We observed an upregulation of cyclins B, D and E, CDK 1, 2, 4 and 6, and p15, p16, p18, p19 and p53 mRNAs (see also Supplementary data 5).
VPA inhibits CLL cell proliferation
We stimulated CLL cell proliferation using CpG oligonucleotides and IL2 to test the effects of VPA (1 mM) on proliferating cells. Proliferation was measured in cells from 16 different patients using a WST1 assay. For each experiment, data were normalized to untreated cells. Figure 5a shows that we stimulated proliferation in all patient cells (Po0.0001), but with variable efficiency. Moreover, we observed that 1 mM VPA could significantly inhibit the induction of proliferation (P ¼ 0.0003). These results were confirmed by cell cycle analysis using PI staining of permeabilized cells. Proliferating cell rates were generally lower than 10%; therefore, by gating cells as a function of their granularity and size, we were able to analyze the effects of VPA on cells proliferating at a higher rate. Cell cycle analysis showed a decrease in cycling cells (Figure 5b ). Furthermore, a simple microscopical observation showed a large number of CLL cell colonies after CpG stimulation, but not in the presence of VPA (Figure 5c ).
Discussion
In this study, we first confirmed the activity of histone deacetylase inhibitors and apoptotic induction potential of VPA after 4 and 24 h of treatment, respectively. These results validated earlier reports on cancer cells, 35 leukemia cells 18 and fresh CLL B cells. [20] [21] [22] Interestingly, we also observe that VPA induces apoptosis in cells from patients with unfavorable cytogenetic abnormalities such as 6q deletion, 17p deletion or showing a complex karyotype (Supplementary data 6). This indicates that the VPA effect would be independent of cytogenetic features, as well as effective in P53-deficient cells that are chemotherapy resistant and associated with a poor outcome. Our caspase activation experiment also showed that apoptotic process began early after VPA addition. Therefore, we analyzed the early and global effects of VPA at 1 mM on the transcriptome after 4 h of treatment. This 4-h period seemed to be the optimal time to observe the primary changes caused by VPA and to avoid too much apoptosis and secondary pathway activations. Furthermore, a preview report on refractory Parametric P-value calulated by a paired t-test on 14 paired samples.
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advanced cancer had shown that 1 mM VPA serum concentration could be easily achieved in humans with relatively low side effects (such as disorientation, confusion or somnolence). 36 Gene expression profiling allowed us to study a large number of genes and to analyze global pathways rather than single targets. Among the 27 367 probe sets considered as present, 60% were significantly modulated and 14% were differentially expressed, with a fold change of 1.5 (increase or decrease) after VPA treatment for 4 h. These rates indicate the broad effects of VPA on transcriptome modulation at a well-tolerated concentration: 57% of probe sets were upregulated, but VPA could also downregulate 43% of them, probably through indirect mechanisms. Indeed, repression of gene transcription by HDAC inhibitors is rather counterintuitive because the decompaction of the chromatin should logically allow gene expression. The donwregulation of genes could result from the transcription of regulatory factors that negatively regulate genes transcription. One of the first anticancer mechanisms of VPA identified was the restoration of expression of key genes that were modified in cancer transformation. Indeed, cancer has been associated with alterations in the epigenetic code leading to abnormal gene expression. 37 In 2004, Wang et al. 38 conducted a meta-analysis comparing CLL with normal B-cell gene expression profiles and identified a number of genes that were differentially expressed between CLL and normal samples. Several genes described as overexpressed in CLL (for example, CD5, BCL2, CD23, LCK and PIM1) were downregulated by VPA, whereas genes described as underexpressed in CLL (for example, BCLA1, c-MYC, DUSP2 and PEA15) were upregulated by VPA. These results indicate that VPA could restore a more 'normal' epigenetic code and, in this way, could allow normal cellular processes that were silenced after malignant transformation. More globally, our gene expression profiles revealed molecular changes in two key pathways involved in cancer: apoptosis and proliferation.
Compared with normal B cells, CLL B cells are characterized by defects in apoptosis. Restoring the capacity for programmed death is, therefore, an important goal in CLL treatment. Our group recently reported that VPA could induce apoptosis by downregulation of c-FLIP(L). 20 Interestingly, the response to VPA was similar among patients with a good or poor prognosis. Bokelmann and Mahlknecht 21 showed that the BCL2/BAX ratio decreased after VPA treatment, indicating a tendency toward apoptosis. Our microarray results were completely in line with these two reports: no differences among the gene expression profiles of ZAP70 þ and ZAP70 À patients (poor and good prognosis, respectively) were found, indicating that VPA was acting independently of disease aggressiveness. Moreover, we observed upregulation of caspase 8 mRNA but also caspase 2, 3, 6, 9 and 10 mRNA, in addition to a twofold downregulation of FLIP mRNA. Large-scale oligonucleotide profiles allowed us to study not only a simplified pro/antiapoptotic gene balance (for example, BCL2/BAX ratio), but also global modulation of apoptotic pathways. We observed the upregulation of key genes, such as APAF1 and P53, and the downregulation of important apoptosis inhibitors, such as BCL-XL, XIAP, AVEN and cIAP. In our recent study, 20 we showed by indirect methods based on caspase inhibitors that VPA selectively activated the caspase-8-dependent (extrinsic) but not the caspase-9-dependent (intrinsic) pathway of apoptosis. Similarly, Bokelmann and Mahlknecht 21 reported that caspase 8 was the first caspase activated by VPA, but a mitochondrial amplification loop seemed to be required. We confirmed these results by a direct quantification of activated caspases. In this study we observed caspase 8 activation, but, in our experimental conditions (1 mM of VPA for 72 h), we were not able to prove caspase 9 activation. However, we observed that caspase 9 mRNA was significantly increased whereas BCL2 and BCL-XL mRNA were significantly decreased. We also confirmed BCL2 downregulation at the protein level, and Bokelmann and Mahlknecht 21 showed that 480% of caspase 9 were cleaved after 72 h of VPA treatment at 3 mM. We can thus speculate that upregulation of proapoptotic factors and repression of antiapoptotic genes induced by VPA could promote or at least restore apoptosis by activating first the extrinsic pathway and then the intrinsic pathway, which thus amplifies the apoptosis signal.
These findings allow a number of clinical applications, the most interesting being the combination of VPA with agents already used to treat CLL to overcome spontaneous or acquired chemotherapy resistance or simply to reduce the therapyassociated toxicity. VPA is currently being tested alone or in combination with other agents mostly in hematological malignancies, 24 but there is increasing interest in testing on solid tumors. 23, 25, 36, 39 Resistance to chemotherapy is a major problem in leukemia treatment, and despite the efficiency of fludarabine in the induction of clinical responses in CLL, resistance to this drug has been well documented. 40, 41 Furthermore, new drugs in clinical trials with powerful apoptotic potential (for example, flavopiridol) can cause many side effects such as anemia, thrombocytopenia, infections, diarrhea and fatigue. 42 Lenalidomide, a novel therapeutic agent with an uncertain mechanism, can lead to sepsis, renal failure, tumor flare resulting in hospitalization or even fatal outcomes. 43 Here, we reported that the combination of VPA with fludarabine, bortezomib, flavopiridol, thalidomide or lenalidomide significantly reduced the IC50 of each drug. In other words, VPA increased the efficacy of each drug and, in the same manner, 55 kDa VPA P a t i e n t A P a t i e n t B P a t i e n t C P a t i e n t D VPA VPA VPA could reduce dose-dependent toxicity. However, it should be noted that drug combination side effects (neurotoxicity, tumor flare, renal failure, effect on normal cells, etc.) are thus far unknown and have to be analyzed in vivo. The first answer to these questions can be given by a phase II clinical trial combining VPA with fludarabine in CLL patients, which is currently in progress (NCT00524667). This chemosensibility induced by VPA treatment could be associated with the reduction of ABCB4 mRNA (ATP-binding cassette, sub-family B (MDR/TAP), member 4 also known as multidrug resistance 3) after VPA treatment. ABCB4 has been proposed to act in the same way as ABCB1 (or multidrug resistance 1), a multidrug efflux pump overexpressed in many cancers, which is associated with RAI stage in CLL. 44, 45 We were, however, unable to confirm this hypothesis by a functional assay using a fluorescent multidrug resistance indicator (data not shown). The increased apoptosis observed when VPA was associated with various drugs seems to be an additive effect after 24 h: indeed, the sum of VPA-induced and drug-induced cell death is very close to the cell death induced by their association (except for bortezomib, for which a clear synergistic effect is observed). Bouzar et al. 22 also observed that VPA acted in an additive/synergistic manner with fludarabine and cladribine to induce apoptosis. In this study, we did not observe a high synergistic effect for fludarabine, probably because of the different experimental conditions used (technique, viability vs apoptosis; time of treatment, 24 vs 48 h; concentration, 7 vs 1 mM). However, we can speculate that the VPA-drug combination is at least additive and, in certain conditions, synergistic. Furthermore, it should be noted that, besides the molecular effect of VPA, the structural changes induced by hyperacetylation caused by VPA could also increase the access to DNA-incorporating agents such as fludarabine, enhancing their anticancer activity.
Recent investigations suggest that the progressive accumulation of CLL B cells in peripheral blood and the bone marrow results not only from defects in apoptosis but also from cell proliferation. 4 Indeed, the bone marrow, lymph nodes and spleen are all sites of leukemic cell proliferation. 5 Our microarray data showed modulation of a large number of cell cycle-related genes. A majority of these genes were upregulated, such as not only CDK1, 2, 4 and 6, cyclin B1, B2, D1, D2, E1 and E2, but also inhibitors of the cell cycle, such as p15, 16, 18, m. values for all tested drugs with or without VPA. (g) After normalization with untreated controls, cell viability was assessed by Trypan blue exclusion assay using the earlier calculated IC50 values (see (f)). Statistical differences were assessed using the Student's paired t-test.
19 and 21. The upregulation of p21 by VPA was observed earlier in myeloid leukemia 28 and multiple myeloma. 46 Similar results have been observed for cyclin D1 and cyclin E in acute leukemia. 17, 47 It is likely that VPA disturbs cell cycle genes, expression of which must be tightly and sequentially regulated. The deregulated and simultaneous expression of all of these genes is probably one of the reasons for proliferation inhibition. Using in vitro functional tests, we showed that VPA could significantly inhibit proliferation of CLL B cells stimulated by IL2 and CpG oligonucleotides. Our data suggest that VPA has an antiproliferative effect on CLL B cells. Interestingly, proliferation and apoptosis are interconnected by overexpression of CDK2, because Gil-Gomez et al. 48 described that upregulation of CDK2 could accelerate cell death via a distinct apoptotic pathway. All these new observations support the argument for the use of VPA in CLL treatment.
In conclusion, this report shows that a well-tolerated concentration of VPA could restore apoptosis, inhibit CLL cell proliferation and potentiate chemosensitivity. Taken together, our data strongly suggest the introduction of VPA in CLL treatment, particularly in combination with other drugs and in refractory patients. 
